Polish pharmaceutical and biotech company meets the challenges of modern medicine

THE Adamed Group is a pharmaceutical and biotechnology company that manufactures and distributes products worldwide. With a portfolio consisting of over 250 products sold in nearly 60 countries, the company is one of the 10 largest pharmaceutical companies operating in Poland. Over the last 16 years, Adamed has invested 225 million euros in research and development and holds 94 pharmaceutical patents.

The company’s strong position is built on an innovative approach shared not only by the management board but also 1,600 employees. More than 150 scientists from leading Polish academic centers collaborate with the Adamed Group in the search for effective therapies.

Adamed produces medications that focus on 14 therapeutic areas, including: allergology and pulmonology, angiology,
antibiotics treatment, diabetology, gastroenterology, gynaecology, cardiology, painkillers, neurology, ophthalmology, dementia medication, psychiatry, rheumatology and urology. Adamed operates one of the first biotechnological and bio-fermentation lines in Poland, its own genetically modified organisms (GMO) lab and a panel of cancerous cell lines which was designed by the American National Cancer Institute to research cancer-fighting particles.

Adamed was established in 1986 by Dr. Marian Adamkiewicz, who opened the company’s first manufacturing plant. In the early 2000s, Adamed was granted the EU’s Good Manufacturing Practices (GMP) certificate, which allowed the company to export pharmaceuticals throughout Europe.

The Adamed Group was founded in 2010 after Adamed acquired Polfa Pabianice and Agropharm (now called Adamed Consumer Healthcare). After years of research, Adamed began the ONCOTRAIL project in 2015 to perform the initial phase of clinical trials for an anti-cancer molecule. This year, Adamed opened an advanced research and development center to further improve the medicines currently available on the market and research new therapies and solutions for oncology and central nervous system diseases.

Maciej Adamkiewicz is a certified surgeon and has been the company’s President of the Board since 2000. He is a member of the International Urogynecological Association and the Polish Meno and Adropause Association. He has been published in Polish and international medical journals, including the International Uroginecology Journal. Adamkiewicz was awarded the Cross of Merit by the President of Poland. His wife, the medical doctor, Małgorzata Adamkiewicz Ph.D., is the CEO of Adamed Group and the vice president of Adamed Pharma. She has been working at the company since it was founded and is responsible for the R&D department and researching new drugs. She too was awarded the Cross of Merit.

Adamed has invested 225 million euro in research and development and holds more than 94 pharmaceutical patents.

Over the years, Adamed received numerous awards for its research and position on the market. In 2008, Adamed was
named “Most Innovative Company in Poland” by the Institute of Economics of the Polish Academy of Sciences as well as “Most Innovative Company in the Healthcare Sector” and in 2009, was recognized for receiving the highest number of patents in that year. The company was listed as “Business Leader” of the pharmaceutical industry by Forbes Magazine in its “Business Leaders 2009” ranking. The Adamed Group was named the “Market Innovation Leader” and won both the “Reliable in Business Award” as well as the “WPROST Innovator Award” in 2012. Most notably, Adamed was nominated for the Economic Award of the Republic of Poland in the “Innovation” category—the only Polish pharmaceutical company to be nominated.

Thanks to its achievements, Adamed is Poland’s ambassador worldwide proving high skills, experience and talent of Polish scientists. Additionally, the Adamed Group Foundation creates educational programs aimed at young talented students.